Wedbush Reiterates Outperform on Verona Pharma, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Liana Moussatos reiterated an Outperform rating on Verona Pharma (NASDAQ:VRNA) and maintained a $33 price target.

March 01, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Liana Moussatos reiterated an Outperform rating on Verona Pharma and maintained a $33 price target.
The reiteration of an Outperform rating and the maintenance of a $33 price target by a reputable analyst like Liana Moussatos from Wedbush is likely to instill confidence among investors and could lead to a positive short-term impact on VRNA's stock price. Analyst ratings and price targets are significant indicators for investors, and positive reaffirmations like this can drive investor sentiment and stock performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100